Home LiteratureArticle Details
PMID: 19707201 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas.

British journal of cancer ·Vol. 101 ·No. 6 ·2009-09-15 ·Pages 973-82

Martinho O, Longatto-Filho A, Lambros MB, Martins A, Pinheiro C, Silva A, Pardal F, Amorim J, Mackay A, Milanezi F, Tamber N, Fenwick K, Ashworth A, Reis-Filho JS, Lopes JM, Reis RM

Abstract

Malignant gliomas are the most prevalent type of primary brain tumours but the therapeutic armamentarium for these tumours is limited. Platelet-derived growth factor (PDGF) signalling has been shown to be a key regulator of glioma development. Clinical trials evaluating the efficacy of anti-PDGFRA therapies on gliomas are ongoing. In this study, we intended to analyse the expression of PDGFA and its receptor PDGFRA, as well as the underlying genetic (mutations and amplification) mechanisms driving their expression in a large series of human gliomas. PDGFA and PDGFRA expression was evaluated by immunohistochemistry in a series of 160 gliomas of distinct World Health Organization (WHO) malignancy grade. PDGFRA-activating gene mutations (exons 12, 18 and 23) were assessed in a subset of 86 cases by PCR-single-strand conformational polymorphism (PCR-SSCP), followed by direct sequencing. PDGFRA gene amplification analysis was performed in 57 cases by quantitative real-time PCR (QPCR) and further validated in a subset of cases by chromogenic in situ hybridisation (CISH) and microarray-based comparative genomic hybridisation (aCGH). PDGFA and PDGFRA expression was found in 81.2% (130 out of 160) and 29.6% (48 out of 160) of gliomas, respectively. Its expression was significantly correlated with histological type of the tumours; however, no significant association between the expression of the ligand and its receptor was observed. The absence of PDGFA expression was significantly associated with the age of patients and with poor prognosis. Although PDGFRA gene-activating mutations were not found, PDGFRA gene amplification was observed in 21.1% (12 out of 57) of gliomas. No association was found between the presence of PDGFRA gene amplification and expression, excepting for grade II diffuse astrocytomas. The concurrent expression of PDGFA and PDGFRA in different subtypes of gliomas, reinforce the recognised significance of this signalling pathway in gliomas. PDGFRA gene amplification rather than gene mutation may be the underlying genetic mechanism driving PDGFRA overexpression in a portion of gliomas. Taken together, our results could provide in the future a molecular basis for PDGFRA-targeted therapies in gliomas.

MeSH Terms
Adolescent Adult Aged Brain Neoplasms/chemistry,genetics Child Child, Preschool Female Gene Amplification Gene Dosage Glioma/chemistry,genetics Humans Male Middle Aged Mutation Platelet-Derived Growth Factor/analysis,genetics Receptor, Platelet-Derived Growth Factor alpha/analysis,antagonists & inhibitors,genetics Signal Transduction
Chemicals
Platelet-Derived Growth Factor platelet-derived growth factor A Receptor, Platelet-Derived Growth Factor alpha
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Martinho O
Life and Health Sciences Research Institute, School of Health Sciences, University of Minho, 4710 Braga, Portugal.
Longatto-Filho A
Lambros M B K
Martins A
Pinheiro C
Silva A
Pardal F
Amorim J
Mackay A
Milanezi F
Tamber N
Fenwick K
Ashworth A
Reis-Filho J S
Lopes J M
Reis R M
References (72)
72 references, click to expand
  1. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Neuro Oncol. 2008 Jun;10(3):330-40 PMID: 18359865
  2. PDGF receptors as cancer drug targets.
    Cancer Cell. 2003 May;3(5):439-43 PMID: 12781361
  3. Screening for copy-number alterations and loss of heterozygosity in chronic lymphocytic leukemia--a comparative study of four differently designed, high resolution microarray platforms.
    Genes Chromosomes Cancer. 2008 Aug;47(8):697-711 PMID: 18484635
  4. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
    Lab Invest. 2008 May;88(5):491-503 PMID: 18332872
  5. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.
    Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12 PMID: 18077431
  6. Coexpression of platelet-derived growth factor (PDGF) and PDGF-receptor genes by primary human astrocytomas may contribute to their development and maintenance.
    J Clin Invest. 1990 Jul;86(1):131-40 PMID: 2164040
  7. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    J Cell Physiol. 2006 Jul;208(1):220-8 PMID: 16575905
  8. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas.
    Clin Cancer Res. 2008 Jun 1;14(11):3386-94 PMID: 18519768
  9. Platelet-derived growth factor in human glioma.
    Glia. 1995 Nov;15(3):257-63 PMID: 8586462
  10. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas.
    Neurosurgery. 1998 Feb;42(2):341-6 PMID: 9482185
  11. Expression of oligodendroglial differentiation markers in pilocytic astrocytomas identifies two clinical subsets and shows a significant correlation with proliferation index and progression free survival.
    J Neurooncol. 2008 Jan;86(2):183-90 PMID: 17690840
  12. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus.
    Cancer Res. 1998 Dec 1;58(23):5275-9 PMID: 9850047
  13. Resolving the resolution of array CGH.
    Genomics. 2007 May;89(5):647-53 PMID: 17276656
  14. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast.
    J Pathol. 2008 Aug;215(4):398-410 PMID: 18484683
  15. Prognostic value of platelet derived growth factor alpha receptor expression in grade 2 astrocytomas and oligoastrocytomas.
    J Neurol Neurosurg Psychiatry. 2002 Jun;72(6):782-7 PMID: 12023424
  16. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
    J Clin Oncol. 2005 Jan 1;23(1):49-57 PMID: 15545668
  17. Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors.
    J Neurosurg. 1991 Sep;75(3):447-51 PMID: 1651380
  18. The discovery of receptor tyrosine kinases: targets for cancer therapy.
    Nat Rev Cancer. 2004 May;4(5):361-70 PMID: 15122207
  19. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-alpha and their receptors in human malignant glioma cell lines.
    Cancer Res. 1988 Jul 15;48(14):3910-8 PMID: 2454731
  20. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
    J Neurooncol. 2007 May;83(1):53-60 PMID: 17245623
  21. Mutation analysis of B-RAF gene in human gliomas.
    Acta Neuropathol. 2005 Feb;109(2):207-10 PMID: 15791479
  22. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
    Curr Opin Investig Drugs. 2007 Dec;8(12):1009-21 PMID: 18058572
  23. Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity.
    J Cancer Res Clin Oncol. 2006 Sep;132(9):589-99 PMID: 16736141
  24. Amplification of alpha-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin.
    Oncogene. 1992 Apr;7(4):627-33 PMID: 1314366
  25. An integrated genomic analysis of human glioblastoma multiforme.
    Science. 2008 Sep 26;321(5897):1807-12 PMID: 18772396
  26. The 2007 WHO classification of tumours of the central nervous system.
    Acta Neuropathol. 2007 Aug;114(2):97-109 PMID: 17618441
  27. Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment.
    Neurosurg Clin N Am. 2007 Jan;18(1):39-58, viii PMID: 17244553
  28. Oncogenic kinase signalling.
    Nature. 2001 May 17;411(6835):355-65 PMID: 11357143
  29. Evaluation of Phi29-based whole-genome amplification for microarray-based comparative genomic hybridisation.
    Lab Invest. 2007 Jan;87(1):75-83 PMID: 17170740
  30. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas.
    Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14344-9 PMID: 16186508
  31. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    J Pathol. 2008 Dec;216(4):399-407 PMID: 18810758
  32. Real-time quantitative PCR analysis of gene dosages reveals gene amplification in low-grade oligodendrogliomas.
    Am J Clin Pathol. 2005 Jun;123(6):900-6 PMID: 15899783
  33. Unlocking pathology archives for molecular genetic studies: a reliable method to generate probes for chromogenic and fluorescent in situ hybridization.
    Lab Invest. 2006 Apr;86(4):398-408 PMID: 16446704
  34. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.
    J Neurosurg. 2001 Aug;95(2):190-8 PMID: 11780887
  35. PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling.
    Neuron. 2006 Jul 20;51(2):187-99 PMID: 16846854
  36. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features.
    J Neuropathol Exp Neurol. 2000 Jun;59(6):495-503 PMID: 10850862
  37. Molecular targeted therapies and chemotherapy in malignant gliomas.
    Curr Opin Oncol. 2007 Nov;19(6):598-605 PMID: 17906459
  38. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
    Nat Rev Drug Discov. 2002 Jul;1(7):493-502 PMID: 12120256
  39. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
    Breast Cancer Res. 2005;7(5):R788-95 PMID: 16168125
  40. A role for platelet-derived growth factor in normal gliogenesis in the central nervous system.
    Cell. 1988 Apr 22;53(2):309-19 PMID: 2834067
  41. Molecular alterations of KIT and PDGFRA in GISTs: evaluation of a Portuguese series.
    J Clin Pathol. 2008 Feb;61(2):203-8 PMID: 17827398
  42. Spontaneous in vitro transformation of adult neural precursors into stem-like cancer cells.
    Brain Pathol. 2009 Jul;19(3):399-408 PMID: 18637011
  43. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.
    Int J Cancer. 1995 Jan 17;60(2):168-73 PMID: 7829210
  44. Expression of platelet-derived growth factor transcripts in medulloblastomas and ependymomas.
    Pediatr Neurosurg. 1996;24(2):74-8 PMID: 8841077
  45. EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas.
    J Surg Oncol. 2004 Apr 1;86(1):34-40 PMID: 15048678
  46. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines.
    Breast Cancer Res Treat. 2009 Dec;118(3):481-98 PMID: 19169812
  47. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    J Pathol. 2005 Oct;207(2):224-31 PMID: 16021678
  48. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.
    Cell Oncol. 2005;27(5-6):319-26 PMID: 16373964
  49. Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme.
    Neuro Oncol. 2007 Jul;9(3):291-7 PMID: 17504929
  50. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    N Engl J Med. 2001 Apr 5;344(14):1038-42 PMID: 11287973
  51. Robust smooth segmentation approach for array CGH data analysis.
    Bioinformatics. 2007 Sep 15;23(18):2463-9 PMID: 17660206
  52. Characterization of an imatinib-sensitive subset of high-grade human glioma cultures.
    Oncogene. 2006 Aug 10;25(35):4913-22 PMID: 16547494
  53. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study.
    J Clin Oncol. 2008 Oct 1;26(28):4659-65 PMID: 18824712
  54. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
    Clin Cancer Res. 2006 Aug 15;12(16):4899-907 PMID: 16914578
  55. Real-time quantitative PCR analysis of regions involved in gene amplification reveals gene overdose in low-grade astrocytic gliomas.
    Diagn Mol Pathol. 2005 Dec;14(4):224-9 PMID: 16319692
  56. Malignant gliomas in adults.
    N Engl J Med. 2008 Jul 31;359(5):492-507 PMID: 18669428
  57. Pdgfr-alpha in 1p/19q LOH oligodendrogliomas.
    Int J Cancer. 2004 Dec 20;112(6):1081-2 PMID: 15386438
  58. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation.
    Proc Natl Acad Sci U S A. 1988 Oct;85(20):7748-52 PMID: 2845420
  59. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops.
    Cancer Res. 1992 Jun 1;52(11):3213-9 PMID: 1317261
  60. Platelet-derived growth factor (PDGF) and glial tumorigenesis.
    Cancer Lett. 2006 Feb 8;232(2):139-47 PMID: 16139423
  61. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
    J Clin Oncol. 2005 Dec 20;23(36):9359-68 PMID: 16361636
  62. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
    Mol Cancer Res. 2006 Dec;4(12):927-34 PMID: 17189383
  63. ESR1 gene amplification in breast cancer: a common phenomenon?
    Nat Genet. 2008 Jul;40(7):809-10; author reply 810-2 PMID: 18583966
  64. Molecular pathology of malignant gliomas.
    Annu Rev Pathol. 2006;1:97-117 PMID: 18039109
  65. Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas.
    Lab Invest. 1992 Oct;67(4):529-34 PMID: 1434531
  66. Molecular alterations of KIT oncogene in gliomas.
    Cell Oncol. 2007;29(5):399-408 PMID: 17726262
  67. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas.
    Cancer Res. 1996 Jan 1;56(1):164-71 PMID: 8548759
  68. Tyrosine kinase expression in pediatric high grade astrocytoma.
    J Neurooncol. 2008 May;87(3):247-53 PMID: 18193393
  69. Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines.
    J Biol Chem. 1991 Sep 5;266(25):16755-63 PMID: 1653246
  70. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
    N Engl J Med. 2002 Aug 15;347(7):472-80 PMID: 12181401
  71. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors.
    Cancer Res. 1992 Aug 15;52(16):4550-3 PMID: 1322795
  72. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
    Cancer Res. 2002 Jul 1;62(13):3729-35 PMID: 12097282
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
1532-1827
DOI
10.1038/sj.bjc.6605225
Published
2009-09-15
Epub
2009-00-25
Pages
973-82
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2743351
Subset
IM
Grants
Breast Cancer Now · BREAST CANCER NOW RESEARCH CENTRE · United Kingdom
External Links
PubMed source DOI: 10.1038/sj.bjc.6605225 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2